Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer

11/09/2021 | 08:00am EST

Exelixis, Inc. (Nasdaq: EXEL) announced that enrollment is now completed for CONTACT-01, the global, phase 3 pivotal trial evaluating cabozantinib (CABOMETYX?) in combination with atezolizumab (TECENTRIQ?) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an immune checkpoint inhibitor and platinum-containing chemotherapy. CONTACT-01 is a global, multicenter, randomized, phase 3, open-label study that enrolled 366 patients who were randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab and the control arm of docetaxel. The primary endpoint of the trial is overall survival. Secondary endpoints include progression-free survival, objective response rate and duration of response. Results from cohort 7 of the phase 1b COSMIC-021 trial informed the CONTACT-01 trial design. CONTACT-01 is sponsored by Roche and co-funded by Exelixis. More information about the trial is available at ClinicalTrials.gov.


ę S&P Capital IQ 2021
All news about EXELIXIS, INC.
01/18Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapie..
BU
01/10EXELIXIS : Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Prov..
PU
01/10EXELIXIS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/10Exelixis Expects Net Product Revenue of $300 Million for Q4, $1.08 Billion for Full-Yea..
MT
01/09Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Pro..
BU
01/09Exelixis, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter a..
CI
01/06Exelixis to Pay $55 Million to Amend Licensing Deal With Iconic Therapeutics, Gains Ful..
MT
01/06Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antib..
BU
01/05Exelixis, Roche Complete Enrollment in Phase 3 Trial of Kidney Cancer Combination Thera..
MT
01/05Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Developm..
AQ
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Financials (USD)
Sales 2021 1 341 M - -
Net income 2021 166 M - -
Net cash 2021 1 019 M - -
P/E ratio 2021 35,0x
Yield 2021 -
Capitalization 5 499 M 5 499 M -
EV / Sales 2021 3,34x
EV / Sales 2022 2,69x
Nbr of Employees 773
Free-Float -
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 17,38 $
Average target price 28,85 $
Spread / Average Target 66,0%
EPS Revisions
Managers and Directors
Michael M. Morrissey President-Research & Development
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Vicki L. Goodman Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.-0.88%5 499
GILEAD SCIENCES, INC.-3.00%88 346
REGENERON PHARMACEUTICALS-3.21%63 906
VERTEX PHARMACEUTICALS5.22%58 750
WUXI APPTEC CO., LTD.-0.66%54 178
BIONTECH SE-34.36%40 873